Whitfield Advises Ribo Life on its Hong Kong IPO

Press Release   ·   09 January 2026

Overview

The source reports Ribo Life’s global offering and Hong Kong main-board listing.

Proceeds and sponsors

The announcement gives approximately HK $1.83 billion after full exercise of the offer-size adjustment option, with CICC and Citigroup identified as joint sponsors.

Biopharmaceutical focus

Ribo Life is described as developing oligonucleotide medicines, particularly siRNA therapeutics.

Pipeline detail

The source identifies RBD4059, targeting FXI for thrombotic disease, among seven internally discovered clinical assets. Its pipeline and offering-size comparisons are historical source statements, not medical guidance, regulatory approval claims or an assurance that experimental products will reach the market.